Want to see ALDX full AI Analyst Report?
ALDX Stock Chart & Stats
$1.52
$0.06(4.28%)
At close: 4:00 PM EDT
$1.52
$0.06(4.28%)
Day’s Range― - ―
52-Week Range$1.07 - $6.18
Previous Close$1.61
Volume1.23M
Average Volume (3M)1.75M
Market Cap
$91.70M
Enterprise Value$83.54
Total Cash (Recent Filing)$45.09M
Total Debt (Recent Filing)$143.45K
Price to Earnings (P/E)―
Beta2.69
Next Earnings
May 06, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding60,326,420
10 Day Avg. Volume1,276,042
30 Day Avg. Volume1,746,381
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$1.25M
Bulls Say, Bears Say
Bulls Say
Targeted RASP PlatformAldeyra’s RASP-focused small‑molecule platform targets inflammatory drivers across ocular and immune-mediated diseases. A mechanism-based approach with a lead candidate (reproxalap) supports potential multi-indication utility and durable clinical value if trials succeed, aiding long-term commercialization optionality.
Strengthened GovernanceAdding an independent, financially qualified audit committee chair improves oversight, reporting quality, and governance discipline. Stronger board financial expertise reduces execution and compliance risk, which is a durable improvement to investor confidence and capital-marketing access over time.
Historically Modest LeverageAnnual statements show modest debt relative to equity historically, which lowers interest burden and offers financing flexibility. This structural conservatism in capital structure provides resilience versus highly leveraged peers, helping preserve optionality for funding clinical programs.
Bears Say
No Revenue BaseAldeyra remains pre-revenue with no product sales, meaning the business depends entirely on external financing and clinical milestones. Lack of commercial revenue prevents internal cash generation, increases dilution risk, and extends the timeline to durable profitability and margin sustainability.
Persistent Cash BurnConsistent negative operating and free cash flow indicates ongoing funding needs to sustain R&D and operations. The recent TTM deterioration raises near-term financing urgency, increasing the likelihood of dilution or costly capital-raising and constraining long-term strategic optionality.
TTM Balance Sheet VolatilityA large TTM step-change in debt, equity and assets reduces visibility into capital structure and runway. This volatility complicates forecasting and raises refinancing uncertainty, making planning for multi‑phase clinical development and commercialization riskier over the medium term.
Aldeyra Therapeutics News
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.07 and its highest was $6.17 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $91.70M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is May 06, 2027 which is in 265 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Jul 31, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.094 by $0.004.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Overvalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,326,420 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.094. Following the earnings report the stock price went down -3.75%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ALDX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $417.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.05%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.29% Insiders
8.73% Mutual Funds
2.42% Other Institutional Investors
80.58% Public Companies and
Individual Investors